Safety of user-initiated intensification of insulin delivery using Cambridge hybrid closed-loop algorithm
the AP@home, CLOuD, DAN06, and KidsAP Consortia

DOI: 10.1177/19322968221141924
License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record


Link to publication on Research at Birmingham portal
Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm

Julia Ware, MD1,2, Malgorzata E. Wilinska, PhD1,2, Yue Ruan, PhD1, Janet M. Allen, RN1, Charlotte K. Boughton, PhD1,2, Sara Hartnell, BSc1, Lia Bally, PhD4, Carine de Beaufort, PhD5,6, Rachel E. J. Besser, PhD7,8, Fiona M. Campbell, MD9, Katharine Draxlbauer, BNurs10, Daniela Elleri, PhD11, Mark L. Evans, MD1,2, Elke Fröhlich-Reiterer, PhD12, Atrayee Ghatak, MD13, Sabine E. Hofer, PhD14, Thomas M. Kapellen, PhD15, Lalantha Leelarathna, PhD16,17, Julia K. Mader, MD18, Womba M. Mubita, RN19, Parth Narendran, PhD10,19, Tina Poettler, RN18, Birgit Rami-Merhar, PhD20, Martin Tauschmann, PhD20, Tabitha Randell, MD21, Hood Thabit, PhD16,17, Ajay Thankamony, MPhil2, Nicola Trevelyan, MD22, and Roman Hovorka, PhD1,2; on behalf of the AP@home, CLOuD, DAN06, and KidsAP Consortia

Abstract

Objective: Many hybrid closed-loop (HCL) systems struggle to manage unusually high glucose levels as experienced with intercurrent illness or pre-menstrually. Manual correction boluses may be needed, increasing hypoglycemia risk with overcorrection. The Cambridge HCL system includes a user-initiated algorithm intensification mode (“Boost”), activation of which increases automated insulin delivery by approximately 35%, while remaining glucose-responsive. In this analysis, we assessed the safety of “Boost” mode.

Methods: We retrospectively analyzed data from closed-loop studies involving young children (1-7 years, n = 24), children and adolescents (10-17 years, n = 19), adults (≥24 years, n = 13), and older adults (≥60 years, n = 20) with type 1 diabetes. Outcomes were calculated per participant for days with ≥30 minutes of “Boost” use versus days with no “Boost” use. Participants with <10 “Boost” days were excluded. The main outcome was time spent in hypoglycemia <70 and <54 mg/dL.

Results: Eight weeks of data for 76 participants were analyzed. There was no difference in time spent <70 and <54 mg/dL between “Boost” days and “non-Boost” days; mean difference: –0.10% (95% confidence interval [CI] –0.28 to 0.07; P = .249) time <70 mg/dL, and 0.03 (–0.04 to 0.09; P = .416) time < 54 mg/dL. Time in significant hyperglycemia >300 mg/dL was 1.39 percentage points (1.01 to 1.77; P < .001) higher on “Boost” days, with higher mean glucose and lower time in target range (P < .001).

Conclusions: Use of an algorithm intensification mode in HCL therapy is safe across all age groups with type 1 diabetes. The higher time in hyperglycemia observed on “Boost” days suggests that users are more likely to use algorithm intensification on days with extreme hyperglycemic excursions.

Keywords
artificial pancreas, automated insulin delivery, closed-loop, hypoglycemia, personalized medicine, type 1 diabetes
Introduction

Automated insulin delivery systems are becoming increasingly common in clinical practice as more such systems are becoming available.\(^1\)\(^2\) All currently available systems use the hybrid closed-loop (HCL) approach, where the closed-loop algorithm automatically adjusts insulin delivery based on real-time sensor glucose levels, but user-initiated prandial boluses are required for optimal outcomes. These systems have been shown to improve glycemic control and reduce time in hypoglycemia.\(^3\)\(^6\) There are however limitations. Systems may struggle to cope with unusually high glucose levels and/or unusually high insulin requirements, as experienced with intercurrent illness, in the pre-menstrual period, following high-fat meals or during puberty or growth hormone surges. This is often due to inherent safety mitigations that do not allow algorithm-driven insulin delivery to exceed pre-specified amounts. Consequently, users need to administer manual correction boluses to bring glucose back into the target range, contributing to management burden and risk of hypoglycemia with overcorrection.\(^7\)

Qualitative research shows that people with type 1 diabetes increasingly expect closed-loop systems to be able to cope with atypical scenarios.\(^8\)\(^9\)\(^10\) In response, some closed-loop systems, such as the CamAPS FX app, now include a personalizable user-initiated mode of operation, activation of which notifies the algorithm that insulin requirements are higher for a user-defined time period.\(^11\) This has the potential to improve usability, increase time in range, and reduce risk of hypoglycemia associated with standard manual correction doses. However, the safety of this specific user-initiated mode of operation that allows intensification of insulin delivery has not been evaluated. In the present analysis, we explore the relationship between user-initiated intensification of insulin delivery and time spent with glucose levels below the target range when using the Cambridge HCL algorithm, hypothesizing that use of “Boost” mode is not associated with an increase in time spent in hypoglycemia.

Methods

Study Population

We retrospectively analyzed data from four multicenter randomized clinical trials conducted in children, adolescents, adults, and older adults with type 1 diabetes, aged 1 to 80 years.\(^4\)\(^5\)\(^12\)\(^13\) All participants used the CamAPS FX HCL app for a minimum period of eight weeks in the unsupervised home setting. Study participants and parents/caregivers of participants signed informed consent; in line with local ethics committee recommendations, written assent was obtained from minors whenever possible. The studies were approved by independent research ethics committees and national regulatory authorities. Inclusion criteria for the studies included type 1 diabetes diagnosis (World Health Organization criteria) for a minimum of six months (young children) or 12 months (older adults), pump therapy for a minimum of three months, and a baseline glycated hemoglobin of <10% (all except adolescents).
Closed-Loop System

All participants used the CamAPS FX closed-loop app (CamDiab Ltd, Cambridge, UK), running on an unlocked android smartphone and communicating via Bluetooth with the Dana Diabecare RS insulin pump (Sooil Development, Seoul, Korea) and Dexcom G6 (Dexcom, San Diego, CA, USA) continuous glucose monitor (CGM). In this HCL system, a model-predictive control algorithm incorporating adaptive learning automatically adjusts insulin delivery every 8 to 12 minutes to achieve a default nominal glucose target of 104.5 mg/dL. CamAPS FX offers personalizable, user-initiated modes of operation, including “Boost” and “Ease off” modes. Activating “Ease off” mode raises the personal glucose target and reduces algorithm-driven insulin delivery, and additionally stops any insulin delivery if glucose drops below 126 mg/dL. “Boost” mode increases algorithm-driven insulin delivery by approximately 35% for a user-defined period, while remaining glucose-responsive. “Boost” can be used in circumstances of unusually high glucose levels or increased insulin requirements, such as during the pre-menstrual period, for low-grade illness in the absence of significant ketones, to correct post-prandial hyperglycemia or during growth hormone pulses. Once target glucose is reached “Boost” mode will become inactive, irrespective of pre-programmed duration. Study participants were free to use “Boost” mode at any time during the study period; however, no data were collected on reasons for “Boost” use.

Statistical Analysis

For each participant, the following outcomes were calculated per 24-hour segment starting at 00:00 and ending at 23:59 over the eight-week data collection period: time in “Boost” mode; percentage of time in closed-loop; percentage of time with CGM available; mean sensor glucose, standard deviation (SD) and coefficient of variation of sensor glucose; percentage of time with sensor glucose below 70 and 54 mg/dL; percentage of time with sensor glucose above 300 mg/dL; and daily total, basal, and bolus insulin dose. Participant days with <70% time in closed-loop were excluded from the analysis.

To explore the association between “Boost”-use and time in hypoglycemia, each participant day was categorized according to “Boost”-use: Either as “non-Boost day” (time with “Boost” active = 0 minutes) or “Boost day” (time with “Boost” active ≥ 30 minutes). Participant days with “Boost”-use between 1 and 29 minutes were excluded from the analysis. Mean glycemic metrics for all non-Boost days and all Boost days were then calculated per participant. Participants who had <10 non-Boost days or <10 Boost days were excluded from the analysis. Glycemic metrics on Boost versus non-Boost days were compared using a paired *t*-test, non-normally distributed data were winsorized.

Outcomes were calculated using GStat software, version 2.3 (University of Cambridge, UK), and statistical analyses were performed using SPSS, version 27 (IBM Software, Hampshire, UK). Measures are reported as mean ± SD for normally distributed or median (interquartile range [IQR]) for non-normally distributed data. *P* values < .05 were considered statistically significant.

Results

Data from 143 participants aged between 1 and 80 years were analyzed over an eight-week period of HCL use in the home setting. Out of 7983 available days, 7378 days (92%) met the pre-specified inclusion criteria of at least 70% closed-loop use and Boost use of either 0 minutes or ≥ 30 minutes; 76 participants had ≥10 days of Boost use (median 23 days [IQR: 15-29] per participant), and were included in the final analysis.

Glycemic and closed-loop specific outcomes are shown in Table 1. The cohort included 24 children aged 1 to 7 years, 19 children and adolescents aged 10 to 17 years, 13 adults aged 24 to 55 years, and 20 older adults aged 60 to 80 years; 54% of the cohort were men, with an overall mean age of 29.4 ± 12.9 years. Closed-loop usage was high across all age groups at median 99%. The overall mean time with sensor glucose in the target range of 70 to 180 mg/dL was 75% ± 9%. The overall median time “Boost” was active per participant per day was 0.0% (IQR: 0.0-6.2; equivalent of 0.0-89.3 minutes). Time spent in hypoglycemia <70 mg/dL was low overall (2.6% [1.6-4.4]), and highest in very young children (5.2% [3.2-7.7]).

There were 3933 available days for analysis, of which 1785 (45%) had ≥ 30 minutes “Boost” use (Table 2). On “Boost” days, “Boost” mode was activated for a median 103 minutes (83-151). There was no difference in time spent in hypoglycemia <70 and <54 mg/dL between “Boost” days (days with ≥30 minutes “Boost” use) and “non-Boost” days; mean difference −0.10% (95% confidence interval [CI] −0.28 to 0.07; *P* = .249) time <70 mg/dL, and 0.03 (−0.04 to 0.09; *P* = .416) time <54 mg/dL. Time in significant hyperglycemia >300 mg/dL was 1.39 percentage points (1.01-1.77; *P* < .001) higher on “Boost” days, while time in target range 70 to 180 mg/dL was 9.5 percentage points (7.2-11.8; *P* < .001) lower and mean glucose 14.6 mg/dL (12.1-16.9; *P* < .001) higher on “Boost” days. In addition, glucose variability was higher on “Boost” days with mean coefficient of variation of glucose 35%, compared with 31% on “non-Boost” days (mean difference: 3.9% [3.2-4.6, *P* < .001]). Figure 1 shows the trend of time spent in hypoglycemia <70 and <54 mg/dL and time spent in significant hyperglycemia >300 mg/dL per participant on “Boost” versus “non-Boost” days. The observed increase in time spent in significant hyperglycemia >300 mg/dL on “Boost” days was not unexpected and is further explored in the “Discussion.”
Table 1. Participant Characteristics and Outcomes by Study Cohort.

<table>
<thead>
<tr>
<th></th>
<th>Overall (n = 76)</th>
<th>Very young childrena (n = 24)</th>
<th>Children and adolescentsa (n = 19)</th>
<th>Adultsa (n = 13)</th>
<th>Older adultsa (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>29.4 ± 12.9</td>
<td>5.2 ± 1.4</td>
<td>12.4 ± 1.6</td>
<td>39.5 ± 9.8</td>
<td>68.2 ± 4.5</td>
</tr>
<tr>
<td>Sex—no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>35 (46)</td>
<td>12 (50)</td>
<td>9 (47)</td>
<td>6 (46)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Male</td>
<td>41 (54)</td>
<td>12 (50)</td>
<td>10 (53)</td>
<td>7 (54)</td>
<td>12 (60)</td>
</tr>
<tr>
<td>Usage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time using CGM (%)</td>
<td>97 ± 4</td>
<td>95 ± 5</td>
<td>96 ± 3</td>
<td>97 ± 3</td>
<td>99 ± 2</td>
</tr>
<tr>
<td>Time in closed-loop (%)</td>
<td>99 (93-100)</td>
<td>99 (94-100)</td>
<td>98 (91-100)</td>
<td>99 (95-100)</td>
<td>99 (96-100)</td>
</tr>
<tr>
<td>Time in “Boost” (%)</td>
<td>0.0 (0.0-6.2)</td>
<td>0.0 (0.0-6.9)</td>
<td>0.0 (0.0-6.3)</td>
<td>0.0 (0.0-4.2)</td>
<td>0.0 (0.0-6.3)</td>
</tr>
<tr>
<td>Sensor glucose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time in range 70-180 mg/dL (%)</td>
<td>75 ± 9</td>
<td>74 ± 7</td>
<td>71 ± 11</td>
<td>74 ± 6</td>
<td>79 ± 9</td>
</tr>
<tr>
<td>Mean glucose (mg/dL)</td>
<td>145.4 ± 16.0</td>
<td>141.1 ± 13.8</td>
<td>153.2 ± 20.4</td>
<td>146.4 ± 9.1</td>
<td>142.9 ± 15.3</td>
</tr>
<tr>
<td>SD (mg/dL)</td>
<td>54.1 ± 12.2</td>
<td>55.3 ± 9.8</td>
<td>62.2 ± 15.5</td>
<td>54.7 ± 6.8</td>
<td>44.5 ± 6.8</td>
</tr>
<tr>
<td>Coefficient of variation (%)</td>
<td>37 ± 6</td>
<td>39 ± 5</td>
<td>40 ± 6</td>
<td>37 ± 3</td>
<td>31 ± 3</td>
</tr>
<tr>
<td>Time &lt; 70 mg/dL (%)</td>
<td>2.6 (1.6-4.4)</td>
<td>5.2 (3.2-7.7)</td>
<td>2.4 (2.0-3.5)</td>
<td>3.2 (1.7-4.0)</td>
<td>1.5 (1.2-2.2)</td>
</tr>
<tr>
<td>Time &lt; 54 mg/dL (%)</td>
<td>0.4 (0.2-1.0)</td>
<td>1.2 (0.5-1.6)</td>
<td>0.4 (0.2-0.7)</td>
<td>0.7 (0.3-0.8)</td>
<td>0.1 (0.1-0.3)</td>
</tr>
<tr>
<td>Time &gt; 300 mg/dL (%)</td>
<td>1.0 (0.4-2.6)</td>
<td>1.3 (0.6-2.6)</td>
<td>4.0 (9-6.0)</td>
<td>1.4 (0.9-2.3)</td>
<td>0.5 (0.1-0.8)</td>
</tr>
<tr>
<td>Insulin delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total daily insulin dose (U/day)</td>
<td>42 ± 25</td>
<td>17 ± 5</td>
<td>65 ± 29</td>
<td>48 ± 14</td>
<td>45 ± 12</td>
</tr>
<tr>
<td>Total daily basal insulin dose (U/day)</td>
<td>24 ± 18</td>
<td>8 ± 3</td>
<td>40 ± 24</td>
<td>29 ± 10</td>
<td>26 ± 9</td>
</tr>
<tr>
<td>Total daily bolus insulin dose (U/day)</td>
<td>17 ± 8</td>
<td>9 ± 3</td>
<td>25 ± 9</td>
<td>19 ± 5</td>
<td>19 ± 6</td>
</tr>
</tbody>
</table>

Data are mean ± SD or median (IQR) unless otherwise indicated.
Abbreviations: CGM, continuous glucose monitor; IQR, interquartile range; SD, standard deviation.
aVery young children were aged 1 to 7 years, children and adolescents 10 to 17 years, adults 24 to 55 years, and older adults 65+ years.

Table 2. Comparison of Main Glycemic Outcomes on Boost and Non-Boost Days.

<table>
<thead>
<tr>
<th></th>
<th>Boost days</th>
<th>Non-boost days</th>
<th>Mean difference</th>
<th>95% confidence interval</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total available days</td>
<td>1785</td>
<td>2148</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Number of days available per participant</td>
<td>23 (15, 29)</td>
<td>28 (20, 37)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Time using &quot;Boost&quot; (%)</td>
<td>7.2 (5.7, 10.5)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Time using &quot;Boost&quot; (minutes)</td>
<td>103 (83, 151)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Time in hypoglycemia (%) &lt;70 mg/dL</td>
<td>3.18 ± 1.91</td>
<td>3.28 ± 1.88</td>
<td>-0.10 [-0.28, 0.07]</td>
<td>.249</td>
<td></td>
</tr>
<tr>
<td>&lt;54 mg/dL</td>
<td>0.60 ± 0.51</td>
<td>0.57 ± 0.51</td>
<td>0.03 [-0.04, 0.09]</td>
<td>.416</td>
<td></td>
</tr>
<tr>
<td>Time in significant hyperglycemia &gt;300 mg/dL (%)</td>
<td>2.37 ± 2.11</td>
<td>0.98 ± 1.36</td>
<td>1.39 [1.01, 1.77]</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>Time in target range 70-180 mg/dL (%)</td>
<td>69.1 ± 13.2</td>
<td>78.6 ± 8.9</td>
<td>-9.5 [-11.8, -7.2]</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>Mean sensor glucose (mg/dL)</td>
<td>153.3 ± 19.6</td>
<td>138.9 ± 14.8</td>
<td>14.6 [12.1, 16.9]</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>Coefficient of variation of glucose (%)</td>
<td>35.2 ± 5.2</td>
<td>31.2 ± 4.9</td>
<td>3.9 [3.2, 4.6]</td>
<td>&lt;.001</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean ± SD or median (IQR). N = 76 participants.
Abbreviations: IQR, interquartile range; SD, standard deviation.

Discussion

The present study reports on the safety of a unique user-initiated insulin delivery intensification mode (“Boost”) during eight weeks of home-use of the Cambridge HCL algorithm by children and adults with type 1 diabetes. There was no difference in time spent in hypoglycemia on days when “Boost” was used compared with “non-Boost” days. This suggests that user-initiated closed-loop insulin delivery intensification is safe to use across all age groups.

The addition of personalizable features in HCL systems is an evolving area. In qualitative studies exploring peoples’
experience using different closed-loop systems, users reported wanting to actively collaborate with the system, to improve glycemic control on days with atypical glucose excursions.9,10,14 Intrinsic day-to-day variability in insulin requirements15,16 can be exacerbated by a variety of factors including intercurrent illness, hormonal fluctuations, and challenging meals.16,17 Closed-loop systems aim to address variability by automatically adjusting insulin delivery based on real-time sensor glucose values, but are more limited in their ability to cope with extreme glucose levels, in contrast to users’ expectations.9 Even in the context of systems incorporating adaptive learning, users felt that being able to communicate new information to the algorithm and influence insulin delivery was important in terms of managing glucose levels at times when the system might not be “aggressive” enough on its own.9,18

“Boost” mode enables users to notify the closed-loop algorithm that insulin requirements are higher than usual. In our study, time spent in significant hyperglycemia >300 mg/dL was higher on “Boost” days, with lower time in target range and higher mean glucose. This was an expected result and suggests that participants use “Boost” on days with more extreme hyperglycemic excursions. An episode of significant hyperglycemia is likely the trigger for “Boost” activation, explaining the higher percentage time >300 mg/dL on days when “Boost” mode was used. In keeping with this suggestion, our results showed that there were fewer “Boost” days than “non-Boost” days, with the majority of participant days not including use of “Boost.” This is reflective of the closed-loop system’s general ability to maintain glucose in the target range at default settings without need for additional user-input, as evidenced by an overall mean time of 75% with glucose in the target range of 70 to 180 mg/dL. The suggestion that “Boost” is primarily used on days with significant hyperglycemia was corroborated by qualitative study findings, where participants reported that activating “Boost” helped the closed-loop system to manage minor illness and atypical hyperglycemia events more effectively.10,19 Improving the closed-loop system’s ability to cope with significant hyperglycemia events may help to improve overall glycemic control and system usability.

Incorporating user-initiated increased insulin delivery into the closed-loop algorithm itself has potential safety benefits. Using manual insulin correction doses or temporary basal rates to manage significant hyperglycemia carries an inherent risk of resultant hypoglycemia.7 Appropriate dosing decisions rely on the accuracy of a range of settings, as well as the timing of the corrective insulin dose itself, making dosing decisions a challenging task.7 In contrast “Boost” enables an increase in algorithm-driven insulin delivery adjusted continuously based on sensor glucose values, with the algorithm using parameters based on adaptive learning, rather than pre-defined settings. When glucose levels have returned to target, “Boost” becomes inactive, regardless of pre-programmed duration. In our study, there was no difference in time spent in hypoglycemia on “Boost” days, emphasizing the potential benefit of advanced technologies in terms of managing extreme glucose excursions safely.

The strengths of our study include the broad age-range of participants between 1 and 80 years and the multicenter, multinational study design with home use of the HCL system without remote monitoring. The longer eight-week study

Figure 1. Individual participants’ time spent with glucose in level 1 hypoglycemia <70 mg/dL (a), overall mean shown in red; level 2 hypoglycemia <54 mg/dL (b), overall mean shown in red; and in significant hyperglycemia >300 mg/dL (c), overall mean shown in red, during days when no “Boost” was used and days when “Boost” was used ≥30 minutes.
period has been shown to provide representative data for mean glucose, glucose variability, and time spent with glucose below, within, and above the target range, supporting the generalizability of our findings. We included only participants with at least 10 “Boost” days and 10 “non-Boost” days, reducing the risk of selection bias. Limitations include the retrospective analysis and the fact that time spent with “Boost” active and time spent in hypoglycemia was calculated on a day-by-day basis rather than an individual event basis. This approach does not allow for any assessment of efficacy of “Boost” and has the potential of underestimating delayed hypoglycemia events following “Boost”-use.

Conclusions

In summary, the use of a user-initiated insulin delivery intensification mode is safe in children, adolescents, adults, and older adults with type 1 diabetes using the Cambridge HCL algorithm. Increasingly, users expect systems to be personalizable as well as individually adaptable. Further studies are warranted to assess whether such personalizable closed-loop features could improve glycemic control while maintaining the safe use of these systems.

Abbreviations

CGM, continuous glucose monitor; CI, confidence interval; HCL, hybrid closed-loop.

Acknowledgments

The authors thank study volunteers for their participation in the studies and acknowledge support by the staff at the Addenbrooke’s Wellcome Trust Clinical Research Facility. Josephine Hayes, Matthew Haydock, Nicole Ashcroft, and Alina Cezar (University of Cambridge); as well as Meena Murthy and Lidiya Varghese (Cambridge Clinical Trials Unit) provided administrative support.

Author Contributions

JW, YR, MEW, and RH co-designed the analysis. JW, YR, MEW, and RH carried out or supported data analysis, including statistical analysis. JW wrote the manuscript. MEW, JMA, CKB, LB, CdB, REJB, FMC, ELR, AG, SEH, TMK, LL, BR-M, MT, TR, HT, AT, NT, and RH co-designed the clinical studies. RH designed the control algorithm. JW, M EW, JMA, CKB, SH, LB, CdB, REJB, FMC, KD, DE, MLE, EF-R, AG, SEH, TMK, LL, JKM, WMM, PN, TP, BR-M, MT, TR, HT, AT, and NT screened and enrolled participants, provided patient care, and/or took study samples. M EW, JMA, CKB, SH, LB, CdB, REJB, FMC, KD, DE, MLE, EF-R, AG, SEH, TMK, LL, JKM, WMM, PN, TP, BR-M, MT, TR, HT, AT, and NT critically reviewed the manuscript. JW, M EW, and RH are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RH reports having received speaker honoraria from Eli Lilly, Dexcom, and Novo Nordisk; receiving license fees from BBraun; patents related to closed-loop; and being director at CamDiab. JW reports receiving speaker honoraria from Ypsomed. YR is a consultant at CamDiab. M EW is a consultant at CamDiab and reports patents related to closed-loop. CKB reports receiving consultancy fees from CamDiab and speaker honoraria from Ypsomed. SH reports speaker and advisory board fees from Dexcom, Medtronic, Sanofi, and Ypsomed; being director at ASK Diabetes Ltd; and receiving consulting/training fees from CamDiab. LB reports receiving research support from Dexcom and CamDiab. REJB reports receiving speaking honoraria from Eli Lilly and Springer Healthcare, and sitting as a voluntary unpaid member of the NovoNordisk UK Foundation Research Selection committee. FMC reports receiving speaker honoraria from Eli Lilly, Dexcom, and Novo Nordisk and Insulet, and consultancy fees from Abbott Diabetes Care. EF-R reports having received speaker honoraria from Eli Lilly and Novo Nordisk, serving on advisory boards for Eli Lilly and Sanofi. M LE is a clinical trialist with or has served on advisory boards or received speakers or writers fees from Medtronic, Dexcom, Abbott Diabetes Care, Roche, AstraZeneca, Novo Nordisk, Eli Lilly, Zucara, Pila Pharma, and Imcyse Pharma. SEH has received speaker honoraria by Eli Lilly, Vertex, Minimed Medtronic, Insulet, Ypsomed, and Sanofi. TMK reports having received speaker honoraria from Eli Lilly and Novo. LL has received personal fees from Abbott Diabetes Care, Dexcom, Insulet, Medtronic, Novo Nordisk, Sanofi, and Diabetes Care. JKM is a member on the advisory board of Boehringer Ingelheim, Becton-Dickinson, Eli Lilly, Medtronic, Prediktor A/S, Roche Diabetes Care, and Sanofi-Aventis, and received speaker honoraria from Abbott Diabetes Care, AstraZeneca, Becton-Dickinson, Dexcom, Eli Lilly, Mereke Sharp & Dohme, NovoNordisk, Roche Diabetes Care, Sanofi, Servier, and Ypsomed. TR reports receiving speaker honoraria from Novo Nordisk and consultancy fees from Abbott Diabetes Care. HT reports receiving research support from Dexcom and speaker honoraria from Eli Lilly. MT reports having received speaker honoraria from Eli Lilly, Novo Nordisk, and Medtronic and advisory board fees from Abbott Diabetes Care. BR-M has received speaker honoraria from Abbott Diabetes Care, Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi, and Menarini and has been on the advisory boards of Eli Lilly, Roche Diabetes Care, and Abbott Diabetes Care. CdB has received speaker honoraria from Minimed Medtronic, and has been member of their European Psychology and e-learning Advisory Board. JMA reports training fees from CamDiab. DE, WMM, PN, TP, AG, AT, KD, and NT have no disclosures.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Institute for Health Research EME Grant (14/23/09); JDRF; Helmsley Trust (#2016PG-T1D046); National Institute for Health Research Cambridge Biomedical Research Centre; Horizon 2020 (grant agreement no. 731560); National Institute of Diabetes and Digestive and Kidney Diseases (1DP3DK112176-01), and Wellcome Trust Strategic Award (100574/Z/12/Z). Dexcom supplied discounted continuous glucose monitoring devices and sensors for the studies. The views expressed...
are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or other funders. No sponsor had any role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.

**ORCID iDs**

Julia Ware [https://orcid.org/0000-0002-4497-0979](https://orcid.org/0000-0002-4497-0979)
Charlotte K. Boughton [https://orcid.org/0000-0003-3272-9544](https://orcid.org/0000-0003-3272-9544)
Rachel E. J. Besser [https://orcid.org/0000-0002-4645-6324](https://orcid.org/0000-0002-4645-6324)
Mark L. Evans [https://orcid.org/0000-0001-8122-8987](https://orcid.org/0000-0001-8122-8987)
Lalantha Leelarathna [https://orcid.org/0000-0001-6076-6997](https://orcid.org/0000-0001-6076-6997)
Hood Thabit [https://orcid.org/0000-0001-7854-4233](https://orcid.org/0000-0001-7854-4233)
Roman Hovorka [https://orcid.org/0000-0001-9602-1962](https://orcid.org/0000-0001-9602-1962)

**References**